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Abstract
Rationale: Clinical trials in chronic obstructive pulmonary disease
(COPD) usually require evidence of airflow obstruction and
clinical risk factors. International Classification of Diseases, Ninth
Revision (ICD-9) diagnosis codes or patient-reported physician
diagnoses are often used for epidemiologic studies and performance
improvement programs.
Objectives: To evaluate agreement between these case definitions
for COPD and to assess the comparability of study populations
identified as having COPD not using the clinical trial reference
standard.
Methods:We recruited patients from the COPD Outcomes-
based Network for Clinical Effectiveness and Research Translation
multicenter clinical registry in a cross-sectional study.
Demographics, clinical, and post-bronchodilator spirometry data
were collected at an in-person study visit. The kappa statistic (k) was
used to evaluate agreement. Amultivariable logistic regressionmodel
was used to identify patient characteristics associated with meeting
the trial reference standard.
Measurements and Main Results: A total of 998 (82.8%) of 1,206
study participants met at least one case definition for COPD (of the
998: 91% using ICD-9 codes, 73% using patient-reported physician
diagnosis, 56%using trial reference standard); agreement between case
definitions was poor (k = 0.20–0.26). Lack of airflow obstruction
was the principal (89%) reason patients identified as having COPD
did not meet the trial reference standard. Patients who were black
(vs. white), obese (vs. normal weight), or had depression (vs. not) were
less likely tomeet the trial reference standard (odds ratio [95%CI], 0.37
[0.26–0.53], 0.51 [0.34–0.75], 0.53 [0.40–0.71], respectively).
Conclusions: Findings highlight concerns about the applicability of
findings in clinical trials to patientsmeeting other case definitions for
COPD.
Keywords: COPD; spirometry; ICD-9-CM; comparative
effectiveness; case definitions
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Chronic obstructive pulmonary disease
(COPD), the third leading cause of death in
the United States, is estimated to affect
between 12 and 24 million individuals,
resulting in nearly $50 billion in healthcare
expenditures (1). Worldwide, COPD
represents the fourth leading cause of death
with an estimated prevalence of 64 million
and the 13th highest burden when based on
disability-adjusted life-years (2). According
to the Global Initiative for Chronic
Obstructive Lung Disease guidelines, the
diagnosis of COPD requires the presence of
post-bronchodilator airflow limitation plus
clinical risk factors (e.g., smoking) (2). This
guideline definition is the cornerstone of
eligibility criteria for most clinical trials in
COPD (3). However, epidemiologists, health
services researchers, clinicians, and payers
often rely on COPD-related International
Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9) diagnosis
codes, or on patient-reported physician
diagnosis to identify patients with COPD (4).
Surprisingly, there is a paucity of data
about the level of agreement between these
three case definitions for COPD, the
characteristics of patients included in each case
definition, and their implications for research
and policy. Such data are needed to interpret
studies using different COPD case definitions
and to assess the applicability of findings in
clinical trials to populations identified using
other COPD case definitions. To address this
gap in knowledge, we conducted a cross-
sectional study using data from the
multicenter National Heart, Lung, and Blood
Institute–sponsored COPD Outcomes-based
Network for Clinical Effectiveness and
Research Translation (CONCERT) DataHub.
Preliminary results of this study have been
previously reported as an abstract (5).
Methods
Study Design and Subject
Recruitment
This cross-sectional study was
one of the primary goals of the
CONCERT–Comparative Effectiveness
Research (CONCERT-CER) program
funded by the National Heart, Lung and
Blood Institute (RC2 HL101618) (6).
Clinical data from healthcare encounters
between 2006 and 2010 at eight US clinical
centers (four academic medical centers,
two community medical centers, and two
integrated health systems) contributed to
the DataHub. The CONCERT DataHub
includes more than 220,000 patients age
40 years or older who have clinical data
suggesting COPD based on ICD-9 diagnosis
codes, pulmonary function data, or
medication lists. See the online supplement
for more information about the DataHub.
A probability sample of patients in the
CONCERT DataHub was contacted to
complete a single in-person study visit.
Written informed consent was obtained
from all patients for the study visit. We
sought to enroll 1,200 participants to
complete in-person study visits. Patients
were excluded from the current study if they
were unable to complete the data collection
procedures described below.
Data Collection and Definitions
An interviewer-administered questionnaire
was used to collect demographics, self-
reported comorbid conditions, and other
clinical information. Measures of height,
weight, and modified Borg dyspnea score
(7) were obtained. Post-bronchodilator
spirometry and 6-minute-walk distance
(6MWD) were performed and interpreted
per the American Thoracic Society standards
(8, 9). The proportion of patients with
a 6MWD less than 350 m was calculated,
because a walk distance below this threshold
is associated with increased mortality (10).
We examined three COPD case definitions:
1. ICD-9 diagnosis codes: patients with
any of the ICD-9 codes commonly used
to identify patients with COPD (11, 12),
in a primary or secondary position in
inpatient or outpatient encounters.
2. Patient-reported physician diagnosis:
patients were asked questions used in
the National Health and Nutrition
Examination Survey (13): “Has a
physician ever said that you have or
had COPD?”, “Has a physician ever said
that you have or had emphysema?” and
“Has a physician ever said that you have or
had chronic bronchitis?” A positive answer
to any of these questions defined patient-
reported physician diagnosis of COPD.
3. Clinical trial reference standard: post-
bronchodilator FEV1/FVC ratio less than
70% plus history of smoking or a1-
antitrypsin deficiency (2). We used a fixed
FEV1/FVC ratio less than 70% because it
is most often used in clinical trials (14, 15).
Statistical Analysis
The kappa statistic (k) was used to determine
the level of agreement between the different case
definitions (16). Bivariate analyses used chi-
square or Fisher exact tests, where appropriate.
A multivariate logistic regression model was
used to identify characteristics of patients
associated with meeting the clinical trial
reference standard. The Hosmer-Lemeshow test
was used to assess the fit of the logistic
regression model. A two-sided a less than 0.05
was considered statistically significant. Statistical
analysis was performed using SAS/STAT v9.3




A total of 1,206 patients completed in-person
visits (36% of patients in the DataHub who
we attempted to contact); of these, 208
were ineligible (87 were unable to perform
spirometry meeting the American Thoracic
Society quality criteria; 121 patients did
not meet any of the three COPD case
definitions). Of the 998 eligible participants,
most were male, white, and overweight
or obese (Table 1). The most prevalent
At a Glance Commentary
Scientific Knowledge on the
Subject: Airflow obstruction plus
clinical risk factors for chronic
obstructive pulmonary disease
(COPD) are used as eligibility criteria
for most clinical trials in COPD. By
contrast, International Classification of
Diseases, Ninth Revision diagnosis
codes and patient-reported physician
diagnoses are used to identify patients
for performance improvement
programs and epidemiologic studies.
What This Study Adds to the
Field: This multicenter study found
poor agreement among the three
different methods of identifying
patients with COPD. The findings raise
concerns about the comparability of
studies using different COPD case
definitions and the applicability of
findings in COPD clinical trials to
patients identified using International
Classification of Diseases, Ninth
Revision diagnosis codes and patient-
reported physician diagnoses.
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comorbidities were hypertension (66%),
depression (42%), and arthritis (36%)
(Table 2). About half reported dyspnea at
rest and had a 6MWD less than 350 m.
Agreement among Case Definitions
Most patients (84%) had multiple
encounters; over half (54%) of patients
were identified by more than one ICD-9
code and 17% by three or more ICD-9
codes at different encounters (Figure 1).
The most common ICD-9 codes that
identified patients as having COPD were
496.x (Chronic airway obstruction NOS,
82%), 491.x (Chronic bronchitis, 31%),
and 492.x (Emphysema, 23%).
Nearly all participants (91%) had
a diagnosis of COPD based on ICD-9 codes,
three-quarters (73%) had a patient-reported
physician diagnosis of COPD, and just over
half (56%) met the clinical trial reference
standard (Figure 2). Only 57% (520 of 909)
and 61% (442 of 726) of patients who met
the ICD-9 and patient-reported physician
diagnosis case definitions, respectively, met
the clinical trial reference standard. The
level of agreement, k, between all three
COPD case definitions was poor (k =
0.20–0.25). Only 42% of patients met all
three case definitions (Figure 2). We did not
observe differences in the distribution of
ICD-9 codes between patients who met and
did not meet the clinical trial reference
standard, but were identified as having
COPD using the other two case definitions
(see Figure E2 and Table E1 in the online
supplement).
Characteristics Associated with
Meeting versus Not Meeting Clinical
Trial Reference Standard
Patients who met the clinical trial reference
standard (n = 438; 44%), were slightly older,
more likely male, white, non-Hispanic, and
had a normal weight or were underweight
(Table 1). They were also more likely to have
a formal education level of high school or less,
and to be a current or former smoker
compared with those who did not meet
the clinical trial reference standard. Lack
of airflow obstruction (FEV1/FVC ,70%,
rather than an absence of a history of
smoking or a1-antitrypsin deficiency) was the
most common reason (89%) that patients did
not meet the trial reference standard. Several
comorbid conditions were less common in
patients who met the trial reference standard:
hypertension, heart failure, depression,
arthritis, and diabetes (Table 2). Cancer was
more common in patients who met the
reference standard. 6MWD (% who walked
,350 m) was similar between groups.
In multivariable analyses, patients who
were black (vs. white), had a college or more
formal education (vs. high school or less),
were obese (vs. normal weight), and had
depression or diabetes were significantly
less likely to meet the clinical trial reference
standard (Table 3). In contrast, patients
who were underweight (vs. normal weight)
or had cancer were more likely to meet the
clinical trial reference standard.
Discussion
In this multicenter study of nearly 1,000
individuals in the United States, we
found poor agreement between three case
definitions commonly used to identify
patients with COPD: ICD-9 diagnosis codes,
Table 1. Demographic Characteristics of Patients Who Met and Did Not Meet the Clinical Trial Reference Standard
Patient Demographics Total Sample (n = 998)
Meets Clinical Trial Reference Standard
P ValueYes* (n = 560) No† (n = 438)
Age, mean (SD) 67 (11) 68 (10) 66 (11) 0.0003
Female, % 43 40 48 0.01
Race, %
White 73 79 66 ,0.0001
Black 22 17 27
Other 5 4 7
Hispanic, % 2 1 3 0.01
Education, %
High school/GED or less 37 41 33 0.003
Some college 40 40 40
College degree1 23 19 27
Income, %
,30,000 46 45 48 0.26
30,000–50,000 27 30 24
50,001–75,000 15 13 16
.75,000 12 11 12
Body mass index, kg/m2, %
,18.5 (underweight) 3 5 0.9 ,0.0001
18.5–24.9 (normal) 22 25 17
25–29.9 (overweight) 30 33 26
>30 (obese) 45 37 56
Smoking status, %
Current 31 33 30 ,0.0001
Former 57 67 43
Never 12 0 27
Younger, nonwhite, obese, women, those with higher education, and never smokers were less likely to meet the trial reference standard. Income was
missing in 12% (11% and 13%) and body mass index was missing in 0.6% (0.5% and 0.7%) of those who met and did not meet the trial reference
standard, respectively.
*(A 1 D 1 E 1 G) and †(B 1 C 1 F) in Figure 2.
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patient-reported physician diagnosis, and
the clinical trial reference standard. These
three case definitions identify overlapping,
but largely different patient populations.
Only 42% of patients were identified as
having COPD by all three methods. Several
demographic (race, education, body-mass
index) and comorbidity (depression,
diabetes, cancer) characteristics significantly
differed between patients who met versus
did not meet the trial reference standard.
Previous studies have reported that
patients with COPD identified using ICD-9
diagnosis codes or patient-reported physician
diagnosis may not have airflow obstruction
on spirometry (17–21). Moreover,
spirometry results may not available at the
point of care. For example, we previously
demonstrated that results of spirometry are
available for only about one in five patients
hospitalized for a COPD exacerbation (20).
A study in five Latin American cities found
that only 36% of patients who reported
a physician diagnosis of COPD had airflow
obstruction on spirometry (21). The current
report adds to this existing literature by
concurrently examining agreement between
three case definitions (physician diagnosis
based on ICD-9 codes, patient-reported
physician diagnosis, clinical trial reference
standard) in a large patient population across
the United States. The poor agreement
between the case definitions (k = 0.20–0.25)
raises concerns about the comparability
of studies using different approaches to
identifying patients with COPD.
A possible explanation for the low level
of agreement is misdiagnosis of COPD.
Overdiagnosis of COPD has been well
documented in previous studies (22–24),
probably because many patients with a
clinical diagnosis of COPD never undergo
Table 2. Clinical Characteristics of Patients Who Met and Did Not Meet the Clinical Trial Reference Standard
Characteristic Total Sample (n = 998)
Clinical Trial Reference Standard
P ValueYes* (n = 560) No† (n = 438)
Comorbid conditions, %
Cardiovascular disease 76 74 78 0.15
Hypertension 66 63 69 0.03
Heart failure 18 16 22 0.01
Coronary artery disease 23 22 24 0.66
Myocardial infarction 19 18 20 0.43
Stroke 15 14 15 0.95
Depression 42 36 50 ,0.0001
Arthritis 36 33 41 0.006
Diabetes 28 22 34 ,0.0001
Cancer history 23 26 19 0.02
Anemia 28 26 30 0.17
Kidney disease 20 18 21 0.30
Dementia 2 2 3 0.15
Dyspnea at rest (Borg), %
0, no dyspnea 52 54 50 0.02
0.5–2, slight 38 38 37
>3, moderate to very severe 10 7 13
Spirometry, post-bronchodilator, %
FEV1/FVC ,70% 61 100 11 ,0.0001
FEV1 ,80% predicted 72 86 55 ,0.0001
6-minute-walk distance, %
Distance walked ,350 m 53 52 54 0.67
Patients who met the trial reference standard are more likely to have airflow obstruction by spirometry but report being less dyspneic. Patients who met the
reference standard also have different prevalence of comorbidities. For example, they are more likely to have hypertension, heart failure, and depression.
Data for 6-minute-walk distance missing in 9% patients (9% and 10%) and dyspnea scores missing in 8% patients (8% and 9%) in those who met and did
not meet the clinical trial reference standard, respectively.
















490.x – Bronchitis NOS
(n=214)




496.x – Chronic airway
obstruction NOS (n=815)
Figure 1. Percentage of participants identified by each International Classification of Diseases, Ninth
Revision (ICD-9) code (n = 909). Most patients (84%) had multiple encounters, and ICD-9 codes may
have varied across these encounters. A total of 54% of patients were identified by more than one
ICD-9 code and 17% by three or more ICD-9 codes.
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confirmatory spirometry (25). Results of
our study indicate that overdiagnosis may
be particularly common among patients
who are black, have more than high-school
education, are overweight or obese, and
have depression or diabetes. Findings
suggest the need for greater use of
confirmatory spirometry, particularly in
these populations.
Alternatively, patients who do not
meet the clinical trial reference standard
may have different COPD disease
phenotype (26). Up to 40% of patients with
radiographically evident emphysema do
not have airflow obstruction when assessed
using spirometry (27, 28). Moreover, the
FEV1/FVC ratio may fail to identify airflow
obstruction in almost 10% of patients
with mixed obstructive and restrictive
pulmonary disease (29). These findings
suggest the need for better characterization
of phenotypes of COPD using lung volume
measurements, diffusion capacity, and
radiographic evaluation in patients with
appropriate clinical findings for COPD but
a normal or increased FEV1/FVC ratio.
Our observations raise the question of
the applicability of findings from clinical
trials (which use the trial reference
standard) to populations identified as
having COPD using other case definitions
and vice versa. For example, only about 60%
of patients with COPD on the basis of ICD-9
diagnosis codes met the clinical trial
reference standard. It is therefore unclear
if the balance of benefits and risks of
therapies observed in research populations
enrolled in clinical trials are also seen in
patients with COPD identified on the basis
of ICD-9 codes or a patient-report of
physician diagnosis in typical clinical
settings.
Results of the current study therefore
raise concerns about the appropriateness
of performance improvement initiatives
(which generally rely on administrative data,
such as ICD-9 codes) to increase use of
medications or other care paradigms that
were established in clinical trial populations.
In other words, quality improvement
initiatives that seek to increase use of COPD
guideline-recommended care (e.g., use of
long-acting bronchodilators or pulmonary
rehabilitation) in populations identified
on the basis of ICD-9 codes alone
(i.e., without confirmation of COPD diagnosis
using spirometry and clinical risk factors)
may or may not offer the benefits observed
in clinical trials. Additionally, findings in
this report suggest that epidemiology studies
that rely exclusively on patient-report of
a physician diagnosis may not accurately
quantify the prevalence, risk factors, or
prognosis of patients with COPD with airflow

































Figure 2. Groups identified as having chronic obstructive pulmonary disease by the different
methods (total n = 998). In this study population, 56% met the clinical trial reference standard (A1 D 1
E 1 G), whereas 44% did not (B 1 C 1 F). Only 42% met all three case definitions (G). Overall there
was poor agreement between the case definitions for chronic obstructive pulmonary disease: (1)
clinical trial reference standard (A1 D1 E1 G) versus patient-reported physician diagnosis (B1 D1
F 1 G), k (95% confidence interval) = 0.26 (0.20–0.31); (2) clinical trial reference standard versus
International Classification of Diseases, Ninth Revision (ICD-9) codes (C 1 E 1 F 1 G), k = 0.20
(0.15–0.24); and (3) patient-reported physician diagnosis versus ICD-9 codes, k = 0.25 (0.15–0.31).
Table 3. Characteristics Associated with Meeting the Clinical Trial Reference Standard




Education (vs. high school or less)
College/professional degree 0.38 (0.26–0.56)*
Some college 0.68 (1.06–2.03)*
BMI, kg/m2 (vs. normal)
,18.5 (underweight) 4.00 (1.27–12.50)*
25–29.99 (overweight) 0.87 (0.58–1.30)
>30 (obese) 0.51 (0.35–0.75)*
Depression (yes vs. no) 0.53 (0.40–0.71)*
Diabetes (yes vs. no) 0.67 (0.48–0.93)*
Cancer (yes vs. no) 1.47 (1.05–2.08)*
Definition of abbreviations: BMI = body mass index; CI = confidence interval.
Clinical trial reference standard (A 1 D 1 E 1 G) versus others (B 1 C 1 F) in Figure 2. Multivariable
logistic regression model that included characteristics listed in Tables 1 and 2 (characteristics
significantly associated with meeting the trial reference standard). Results indicate that patients who
are black (vs. white), with college or higher (vs. high school or less) education, obese (vs. normal
weight), with depression, or diabetes are less likely to meet the trial reference standard. Patients with
a history of cancer and underweight patients (vs. normal weight) are more likely to meet the trial
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patients who reported a physician diagnosis
of COPD met the clinical trial reference
standard. Our findings provide justification
for including measurements of airflow
obstruction by spirometry in epidemiologic
and health services research studies.
Patients who met and did not meet the
clinical trial reference standard had a similar
distribution of ICD-9 codes. Also, results
of a sensitivity analysis using a post-
bronchodilator FEV1/FVC less than lower
limit of normal in the clinical trial reference
standard (rather than a fixed FEV1/FVC
ratio ,70%) indicate limited overlap
between case definitions that use
spirometry-confirmed airflow obstruction,
ICD-9 diagnosis codes, and patient-
reported COPD diagnosis (see Figure E1B)
(30). These findings indicate that it was not
the selection of ICD-9 codes or the fixed
ratio definition of airflow obstruction that
accounted for the low level of agreement
between the different case definitions.
Our study has multiple strengths. To
our knowledge, this is the first study to
concurrently examine the clinical trial
reference standard, ICD-9 codes, and
patient-reported physician diagnosis of
COPD in the same population. Second, this
multicenter study included nearly 1,000
patients at medical centers distributed
across multiple regions of the United States.
Third, our study identified specific
demographic and clinical characteristics
likely to be different in clinical trial
populations and others identified as having
COPD.
This study also has potential limitations.
First, it is possible that patients who
contributed data for the current report do not
reflect the overall population of patients with
COPD at each institution, because only
about one-third of patients we attempted to
contact completed the in-person study visit.
Second, ICD-10 codes are likely to replace
ICD-9 codes in the United States in October
2015 (31). Results of our study may or
may not apply to case definitions that use
ICD-10 codes for COPD. Third, although
our study included eight institutions (four
academic medical centers, two community
medical centers, and two integrated
health systems), it was not designed to
compare differences in the performance
characteristics of the various case definitions
within and across the different types of
healthcare institutions in the United States.
The results of our study could be used to
inform the development and conduct of
adequately powered studies to answer such
questions. Fourth, we did not have results of
chest imaging studies (e.g., chest computed
tomography), which could have helped to
identify radiographic evidence of COPD
in patients without evidence of airflow
obstruction on spirometry. Last, our study used
a cross-sectional design; longitudinal studies
are needed to determine if functional outcomes
(e.g., healthcare use, response to treatment)
differ across the patient populations.
In summary, we found that in
a multicenter US population of nearly 1,000
individuals, the clinical trial reference
standard, ICD-9 codes, and patient-reported
physician diagnosis identify three largely
different populations of patients with
COPD. Findings raise concerns about the
comparability of studies using different
COPD case definitions and the applicability
of findings in COPD clinical trials to clinical
populations identified by ICD-9 diagnosis
codes and patient-reported physician
diagnoses. It is unclear if the poor agreement
between the different methods is caused
by overdiagnosis or different COPD
phenotypes (e.g., radiographic evidence of
emphysema without concomitant airflow
obstruction when measured using
spirometry). Longitudinal studies are
needed to determine if functional outcomes
differ across the patient populations. n
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